Display options
Cite
Xia H, Lee KW, Chen J, et al. Simultaneous silencing of ACSL4 and induction of GADD45B in hepatocellular carcinoma cells amplifies the synergistic therapeutic effect of aspirin and sorafenib. Cell Death Discov. 2017;3:17058doi: 10.1038/cddiscovery.2017.58.
Xia, H., Lee, K. W., Chen, J., Kong, S. N., Sekar, K., Deivasigamani, A., Seshachalam, V. P., Goh, B. K. P., Ooi, L. L., & Hui, K. M. (2017). Simultaneous silencing of ACSL4 and induction of GADD45B in hepatocellular carcinoma cells amplifies the synergistic therapeutic effect of aspirin and sorafenib. Cell death discovery, 317058. https://doi.org/10.1038/cddiscovery.2017.58
Xia, Hongping, et al. "Simultaneous silencing of ACSL4 and induction of GADD45B in hepatocellular carcinoma cells amplifies the synergistic therapeutic effect of aspirin and sorafenib." Cell death discovery vol. 3 (2017): 17058. doi: https://doi.org/10.1038/cddiscovery.2017.58
Xia H, Lee KW, Chen J, Kong SN, Sekar K, Deivasigamani A, Seshachalam VP, Goh BKP, Ooi LL, Hui KM. Simultaneous silencing of ACSL4 and induction of GADD45B in hepatocellular carcinoma cells amplifies the synergistic therapeutic effect of aspirin and sorafenib. Cell Death Discov. 2017 Sep 11;3:17058. doi: 10.1038/cddiscovery.2017.58. eCollection 2017. PMID: 28900541; PMCID: PMC5592242.
Copy Download .nbib Format: NLM
Share it on

Cell Death Discov. 2017 Sep 11;3:17058. doi: 10.1038/cddiscovery.2017.58. eCollection 2017.

Simultaneous silencing of ACSL4 and induction of GADD45B in hepatocellular carcinoma cells amplifies the synergistic therapeutic effect of aspirin and sorafenib.

Cell death discovery

Hongping Xia, Kee Wah Lee, Jianxiang Chen, Shik Nie Kong, Karthik Sekar, Amudha Deivasigamani, Veerabrahma Pratap Seshachalam, Brian Kim Poh Goh, London Lucien Ooi, Kam M Hui

Affiliations

  1. Laboratory of Cancer Genomics, National Cancer Centre, Singapore, Singapore.
  2. Department of Pathology, School of Basic Medical Sciences & Sir Run Run Hospital, Nanjing Medical University, Nanjing, China.
  3. Department of General Surgery, Singapore General Hospital, Singapore, Singapore.
  4. Department of Surgical Oncology, National Cancer Centre, Singapore, Singapore.
  5. Cancer and Stem Cell Biology Program, Duke-NUS Medical School, Singapore, Singapore.
  6. Institute of Molecular and Cell Biology, ASTAR, Biopolis Drive Proteos, Singapore, Singapore.
  7. Department of Biochemistry, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.

PMID: 28900541 PMCID: PMC5592242 DOI: 10.1038/cddiscovery.2017.58

Abstract

Sorafenib is currently the only US Food and Drug Administration (FDA)-approved molecular inhibitor for the systemic therapy of advanced hepatocellular carcinoma (HCC). Aspirin has been studied extensively as an anti-inflammation, cancer preventive and therapeutic agent. However, the potential synergistic therapeutic effects of sorafenib and aspirin on advanced HCC treatment have not been well studied. Drug combination studies and their synergy quantification were performed using the combination index method of Chou-Talalay. The synergistic therapeutic effects of sorafenib and aspirin were evaluated using an orthotopic mouse model of HCC and comprehensive gene profiling analyses were conducted to identify key factors mediating the synergistic therapeutic effects of sorafenib and aspirin. Sorafenib was determined to act synergistically on HCC cells with aspirin

Conflict of interest statement

The authors declare no conflict of interest.

References

  1. Cancer Lett. 2011 Jun 28;305(2):250-62 - PubMed
  2. Clin Cancer Res. 2011 Sep 15;17(18):6040-51 - PubMed
  3. CA Cancer J Clin. 2012 Nov-Dec;62(6):394-9 - PubMed
  4. JAMA Intern Med. 2014 May;174(5):739-41 - PubMed
  5. Cancer Sci. 2003 May;94(5):421-4 - PubMed
  6. Hepatology. 2013 Aug;58(2):629-41 - PubMed
  7. Cancer Metastasis Rev. 2014 Mar;33(1):295-307 - PubMed
  8. Cancer Res. 2010 Nov 15;70(22):9309-18 - PubMed
  9. Acta Biochim Biophys Sin (Shanghai). 2015 Dec;47(12 ):988-96 - PubMed
  10. J Natl Cancer Inst. 2015 Sep 04;107(9):null - PubMed
  11. N Engl J Med. 2008 Jul 24;359(4):378-90 - PubMed
  12. J Hepatol. 2015 Oct;63(4):863-73 - PubMed
  13. CA Cancer J Clin. 2015 Mar;65(2):87-108 - PubMed
  14. Lancet Oncol. 2009 Jan;10(1):25-34 - PubMed
  15. Cancer Res. 2010 Jan 15;70(2):440-6 - PubMed
  16. J Clin Oncol. 2016 Mar 20;34(9):987-1011 - PubMed
  17. PLoS One. 2013 May 31;8(5):e65023 - PubMed
  18. Lancet Oncol. 2012 May;13(5):518-27 - PubMed
  19. Ann N Y Acad Sci. 2009 Feb;1155:206-21 - PubMed
  20. Nat Rev Clin Oncol. 2015 Jul;12(7):408-24 - PubMed

Publication Types